On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

MIT Holding (MITD) Identifies Industry Transition to Value-Based & Ambulatory Care; Moves to Profitability as a Result

MITD logo

The continued growth of the ambulatory (outpatient) care market is driven by a number of emergent factors. The increase in life spans have incubated a prevalence of diseases such as diabetes and COPD (chronic obstructive pulmonary disease) among an increasingly elderly population of retiring Baby Boomers. Insurance carriers are now authorizing payments for more services that that result in more affordable convenience and logistical efficacy of home-based recuperation for these patients, with cost savings of up to 65 percent for minimally invasive procedures when performed at home or in an ambulatory care center. However, it is extremely difficult for already overburdened families to successfully arrange and utilize a comprehensive suite of services, such as home-based infusions, access to durable medical equipment (DME), and the benefits of a comprehensive prescription drug program administrated by a pharmacy benefit manager, by a single healthcare provider (PBM).

MIT Holding Inc. (OTC: MITD) has identified this niche and filled it successfully. Moreover, all participants in the ambulatory care market, whether patients, medical facilities or insurance carriers, benefit directly from tight-knit relationships and the kind of well-oiled networking machinery that MIT Holding offers its patients.

This is particularly important as the industry continues rapidly transitioning from Meaningful Use Stage 1 requirements to the much more complex criteria of Stage 2, where robust clinical reporting that is in-line with regulatory and quality-driven initiatives, as well as coordinated care and patient engagement, are paramount. When it comes to Medicare and Medicaid EHR (electronic health record) Incentive Program participation, healthcare information technology (HCIT) continues to open new doors for the ambulatory care market, and this segment of the overall healthcare market stands to deliver optimum results when it comes to the prevailing value-based care initiatives as well. Patient long-term outcomes and customer service are more of a key focus in ambulatory care than in acute hospital care, and this is a major driving factor of the industry’s continued shift toward ambulatory care.

Organized as a single source provider for a wide range of services and products to patients through its network of affiliates and contractors, MIT Holding is able to hit the sweet spot between cost effective care and customer service. The company delivers intravenous infusions for home and ambulatory care center injection via its full service compounding pharmacy, as well as pharmaceuticals, medical equipment for the home, and other home-based healthcare. The typical high cost of specialized infusion pharmacy services can be substantially ameliorated through ambulatory care, and the kind of customized education/counseling that is also required to get the patient situated regarding their condition and the requisite treatments, is ideally deliverable via the ambulatory care model (again in clear contrast with hospital care).

Saving the patient time and money is also a highly lucrative niche market for MIT Holding, as infusion medications typically require preparation by highly specialized pharmacy operations employing registered pharmacists, and the therapy itself is generally administered by a registered nurse or trained caregiver that ideally has established a good, long-term relationship with the patient.

A growing number of therapies are now deliverable in this fashion as well, making in-home treatment increasingly attractive to patients, and the option of going to a contracted ambulatory care center (the company operates one itself), staffed with full-time nurses and a doctor, in order to receive improved consultation, or assistance in obtaining reimbursement, is seen as a huge advantage to many patients and their families.

This is a big, growing market for MIT Holding, spanning such infusion therapies as total parenteral nutrition for chronic digestive and gastro-intestinal disorders, anti-ineffective therapies for diseases like chronic urinary tract infections, chronic pain management through intravenous or continuous analgesics, and a variety of others. In this same vein, the company’s DME sales and leasing capabilities, with access to a host of devices ranging from wheelchairs and oxygen concentrators, to nebulizers and other sustained-use equipment, provides MIT Holding with a constantly growing amount of Medicaid billing.

The expansion last year of the DME contract by WellPoint’s (NYSE: WLP) Georgia subsidiary, Amerigroup Community Care, to cover all of MIT Holding’s services (including ambulatory, infusion and perinatal), is a prime example of the company’s continually growing post-acute network footprint. Similarly, two contracts awarded more recently by HCIT and post-acute treatment patient transition innovator Curaspan Health Group, which maintains an impressive 98 percent customer retention rate, gave the company real-time access to market its compound pharmaceuticals, infusion services and DME offerings to the patients of over 5,400 Curaspan driven medical facilities nationwide.

The company’s deal with Coastal Carolina Medical Center is another good example here, in that the in-patient treatments MIT Holding was initially engaged to do dovetail exceptionally well with subsequent, more expansive ambulatory care service provisions, generating billing in the $1,000 per treatment range for the company.

With current approval by more than 130 insurance carriers for a variety of medical goods and services, as well as a much more focused core of operations specifically in the home health recovery space, MIT Holding has seriously tightened up its cost and revenue structure subsequent to its reorganization that began in 2011, and currently enjoys a 32 percent net profit standard on sales, services, and the like moving forward. Estimates of up to 90 percent savings for patients who utilize in-home infusion services will continue to be a major contributor to the company’s success, and with the U.S. home infusion market on track to grow 68 percent over the next five years to around $26.7 billion, MIT Holding will be looking to carve an ever-increasing slice of that pie off for its shareholders in years to come.

A continued focus on providing affordable, customer service-driven delivery of high-cost, low volume specialty infusions spells big profit for MIT Holding, and the requisite handling/administration requirements associated with such infusions will help the company maintain a firm grasp on the underlying market’s dynamics. And because MIT Holding handles all its own billing and collection practices via a sophisticated computerized billing framework, obtaining the lion’s share of its revenues from contracts with third party payers, affiliates and contractors, as well as self-pay patients and self-insured employers, the company has unprecedented fluidity when it comes to the claim review and editing process, as well as granular pre-service initiation control driven by rigorous insurance coverage verification and carrier authorization protocols.

For more information visit http://mitholdinginc.com/

Let us hear your thoughts: MIT Holding, Inc. Message Board

Archives

Select A Month
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered